The treatment was well-tolerated throughout the 16 weeks, including eight weeks of treatment and an equal duration of follow-up.436 However, a thorough investigation into the antitumor efficacy and immunomodulatory effects of these peptide-based PCSK9-iTs is essential within cellular and animal preclinical cancer studies. Here, PCSK9 is linked to cancer.